Quest Laboratories Q1 FY26 — “From Antibiotics to Auditors: Smallcap Pharma’s Plot Thickens”

1. At a Glance

Quest Laboratories posted a Q1 FY26 net profit of ₹4.1 Cr (up 177% QoQ), while also pulling a surprise land acquisition worth ₹3.2 Cr — because nothing says “growth” like buying land after an earnings beat. Sales, margins, and EPS all improved. Stock, meanwhile, down 1.8%. Because SME investors can’t have nice things.

2. Introduction with Hook

Imagine if your family chemist store decided to go public, flexed 800 licensed formulations, and then bought land for expansion — all while being smaller than the average Bollywood vanity van budget.

That’s Quest Labs.

With over 272 active products, a Myanmar export order book, and enough formulations to confuse a pharmacology textbook — QLL is punching above its ₹170 Cr weight class.

3. Business Model (WTF Do They Even Do?)

Quest Labs runs a buffet-style pharma business:

• Manufactures generics, OTC, and ethical formulations across antibiotics, antimalarials, anti-inflammatories, respiratory meds, diabetes care, and more.
• Formats include: tablets, liquids, powders, ointments, ORS — basically everything except injectables.
• Sales channels: Institutional, PCD (Propaganda Cum Distribution), Contract Manufacturing, Domestic & Exports (Myanmar flex alert).

They’re like that overachieving kid in school — not top of the class, but quietly doing 20 subjects well.

4. Financials Overview